Prevention of access-related infection in dialysis

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 10, 2009, Pages 1185-1200

  Barraclough, Katherine A ^b   Hawley, Carmel M ^b   Playford, E Geoffrey ^b   Johnson, David W ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Access; Antibiotic; Antimicrobial; Catheter; Hemodialysis; Infection; Peritoneal dialysis; Prophylaxis

Indexed keywords

ALCOHOL; CEFAZOLIN; CEFOTAXIME; CHLORHEXIDINE; CIPROFLOXACIN; CITRATE SODIUM; DISINFECTANT AGENT; GENTAMICIN; METICILLIN; MINOCYCLINE; NYSTATIN; PLACEBO; POLYSPORIN; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN; STAPHYLOCOCCUS VACCINE; TAUROLIDINE; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ASEPSIS; BACTEREMIA; BIOFILM; CATHETER INFECTION; CATHETER REMOVAL; CLINICAL TRIAL; DIALYSIS CATHETER; DISINFECTION; DRUG WITHDRAWAL; EQUIPMENT DESIGN; ERADICATION THERAPY; ESCHERICHIA COLI; FUNGEMIA; HAND WASHING; HEART ARREST; HEMODIALYSIS; HONEY; HOSPITAL ADMISSION; HUMAN; INFECTION PREVENTION; INOCULATION; KIDNEY FAILURE; KLEBSIELLA; LAPAROSCOPIC SURGERY; LAPAROTOMY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL CONTAMINATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; PATHOGENESIS; PATIENT SAFETY; PERITONEAL DIALYSIS; PERITONITIS; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INCISION; STAFF TRAINING; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS; VASCULAR ACCESS;

ANTI-INFECTIVE AGENTS; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; CHEMOPREVENTION; DIALYSIS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 74249116942     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.100     Document Type: Review

References (205)

1. US Renal Data System: USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. NIH, National Institue of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, USA (2008). • Registry data that demonstrates the impact of access-related infections on morbidity and mortality in hemodialysis (HD) patients.
2. Johnson DW, McDonald SP, Excell L, Livingston B, Shtangey V. Peritoneal dialysis. In: ANZDATA Registry Report 2005 (Chapter 6). McDonal SP, Excell L (Eds). Adelaide, South Australia, 87-103 (2006).
3. Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int. 68(1), 311-318 (2005).
4. Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int. 66(6), 2429-2436 (2004).
5. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am. J. Kidney Dis. 44(5), 866-876 (2004).
6. Tordoir J, Canaud B, Haage P et al. EBPG on vascular access. Nephrol. Dial. Transplant. 22(Suppl. 2), ii88-ii117 (2007).
7. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J. Am. Soc. Nephrol. 15(2), 477-486 (2004).
8. USRDS. Exerts from the USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. Am. J. Kidney Dis. 41, S1-S260 (2003).
9. Pisoni RL. Vascular access use and outcomes: results from the DOPPS. Contrib. Nephrol. 137, 13-19 (2002).
10. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann. Intern. Med. 127(4), 275-280 (1997).
11. Sesso R, Barbosa D, Lerne IL et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J. Am. Soc. Nephrol. 9(6), 1085-1092 (1998).
12. Johnson DW, MacGinley R, Kay TD et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol. Dial. Transplant. 17(10), 1802-1807 (2002).
13. Johnson DW, van Eps C, Mudge DW et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J. Am. Soc. Nephrol. 16(5), 1456-1462 (2005). •• Well-conducted randomized, controlled trial demonstrating equivalence of honey with mupirocin for prevention of catheter-associated infection in HD patients.
14. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J. Am. Soc. Nephrol. 10(5), 1045-1049 (1999).
15. Kovalik EC, Raymond JR, Albers FJ et al. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection. J. Am. Soc. Nephrol. 7(10), 2264-2267 (1996).
16. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect. Control Hosp. Epidemiol. 23(12), 716-720 (2002).
17. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am. J. Infect. Control, 32(3), 155-160 (2004).
18. Colville LA, Lee AH. Retrospective analysis of catheter-related infections in a hemodialysis unit. Infect. Control Hosp. Epidemiol. 27(9), 969-973 (2006).
19. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. 26(2), 175-183 (2005).
20. Inrig JK, Reed SD, Szczech LA et al. Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clin. J. Am. Soc. Nephrol. 1(3), 518-524 (2006).
21. Taal MW, Fluck RJ, McIntyre CW Preventing catheter related infections in haemodialysis patients. Curr. Opin. Nephrol. Hypertens., 15(6), 599-602 (2006).
22. Winearls CG, Fluck R, Mitchell DC, Gibbons CP, Kessel D, Moss JG. The Organisation and Delivery of the Vascular Access Service for Maintenance Haemodialyisis Patients: Report of a Joint Working Party. Vascular Access Report. The Renal Association, Clinical Service Committee. 11 (2006).
23. Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am. J. Kidney Dis. 51(2), 233-241 (2008).
24. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 60(4), 1443-1451 (2001).
25. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 62(2), 620-626 (2002).
26. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst. Rev. (4), CD004680 (2004).
27. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst. Rev. (4), CD004679 (2004).
28. Wiggins KJ, Johnson DW, Craig JC, Strippoli GF. Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 50(6), 967-988 (2007).
29. Wiggins KJ, Craig JC, Johnson DW, Strippoli GF. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst. Rev. (1), CD005284 (2008).
30. Fried L, Abidi S, Bernardini J, Johnston JR, Piraino B. Hospitalization in peritoneal dialysis patients. Am. J. Kidney Dis. 33(5), 927-933 (1999).
31. Bernardini J, Bender F, Florio T et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J. Am. Soc. Nephrol. 16(2), 539-545 (2005).
32. Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and trends in Gram-negative infections in peritoneal dialysis patients. Perit. Dial. Int. 23(5), 456-459 (2003).
33. Zimmerman SW, Ahrens E, Johnson CA et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am. J. Kidney Dis. 18(2), 225-231 (1991).
34. Johnson DW, McDonald SP, Excell L, Livingston B, Shtangey V Peritoneal Dialysis. In: ANZDATA Registry Report 2006 (Chapter 6). McDonald SP, Excell L (Eds). Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia, 87-103 (2007).
35. Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int. 103, S55-S62 (2006).
36. Aslam N, Bernardini J, Fried L, Burr R, Piraino B. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 1(6), 1226-1233 (2006).
37. Johnson DW, Dent H, Hawley CM et al. Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am. J. Kidney Dis. 53(2), 290-297 (2009).
38. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am. J. Kidney Dis. 44(5), 779-791 (2004).
39. Kim DK, Yoo TH, Ryu DR et al. Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. Perit. Dial. Int. 24(5), 424-432 (2004).
40. Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002). Nephrol. Dial. Transplant. 19(10), 2584-2591 (2004).
41. Miles R, Hawley CM, McDonald SP et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int. 76(6), 622-628 (2009).
42. Santoianni JE, Predari SC, Veron D, Zucchini A, de Paulis AN. A 15 year-review of peritoneal dialysis-related peritonitis: microbiological trends and patterns of infection in a teaching hospital in Argentina. Rev. Argent. Microbiol. 40(1), 17-23 (2008).
43. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J. Infect. Dis. 168(2), 400-407 (1993).
44. von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 65(2), 179-214 (2005).
45. von Eiff C, Kohnen W, Becker K, Jansen B. Modern strategies in the prevention of implant-associated infections. Int. J. Artif Organs 28(11), 1146-1156 (2005).
46. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int. 66(2), 801-805 (2004).
47. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton, Vic.) 12(4), 321-330 (2007).
48. Dittmer ID, Sharp D, McNulty CA, Williams AJ, Banks RA. A prospective study of central venous hemodialysis catheter colonization and peripheral bacteremia. Clin. Nephrol. 51(1), 34-39 (1999).
49. Davies SJ, Ogg CS, Cameron JS, Poston S, Noble WC. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patientstreated with continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 9(1), 61-64 (1989).
50. Dasgupta MK, Kowalewaska-Grochowska K, Costerton JW. Biofilm and peritonitis in peritoneal dialysis. Perit. Dial. Int. 13(Suppl. 2), S322-S325 (1993).
51. Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am. J. Kidney Dis. 39(6), 1278-1286 (2002).
52. Anwar H, Dasgupta MK, Costerton JW Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob. Agents Chemother. 34(11), 2043-2046 (1990).
53. Brulez HF, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit. Dial. Int. 15(7 Suppl.), S24-S33 (1995).
54. Jorres A, Gahl GM, Frei U. In vitro studies on the effect of dialysis solutions on peritoneal leukocytes. Perit. Dial. Int. 15(Suppl.7), S41-S45 (1995).
55. Pajek J, Kveder R, Bren A et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit. Dial. Int. 28(1), 44-52 (2008).
56. Furkert J, Zeier M, Schwenger V Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit. Dial. Int. 28(6), 637-640 (2008).
57. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit. Dial. Int. 25(3), 248-255 (2005).
58. Sherertz RJ, Ely EW, Westbrook DM et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann. Intern. Med. 132(8), 641-648 (2000).
59. Sanders RA, Sheldon GF. Septic complications of total parenteral nutrition. A five year experience. Am. J. Surg., 132(2), 214-220 (1976).
60. Ryan JA Jr, Abel RM, Abbott WM et al. Catheter complications in total parenteral nutrition. A prospective study of 200 consecutive patients. N. Engl. J. Med. 290(14), 757-761 (1974).
61. Murphy LM, Lipman TO. Central venous catheter care in parenteral nutrition: a review. JPEN J. Parenter. Enteral. Nutr. 11(2), 190-201 (1987).
62. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 355(9218), 1864-1868 (2000).
63. Keohane PP, Jones BJ, Attrill H et al. Effect of catheter tunnelling and a nutrition nurse on catheter sepsis during parenteral nutrition. A controlled trial. Lancet 2(8364), 1388-1390 (1983).
64. Beathard GA. Catheter management protocol for catheter-related bacteremia prophylaxis. Semin Dial, 16(5), 403-405 (2003).
65. NKF-K/DOQI Clinical Practise Guidelines for Vascular Access, Update 2006, Guideline 15: catheter care and accessing the patients circulation. Am. J. Kidney Dis. 37(Suppl. 1), S157-S159 (2001).
66. Maki DG, Band JD. A comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. Am. J. Med. 70(3), 739-744 (1981).
67. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int. 40(5), 934-938 (1991).
68. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and Chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338(8763), 339-343 (1991).
69. Humar A, Ostromecki A, Direnfeld J et al. Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antisepsis for prevention of central venous catheter infection. Clin. Infect. Dis. 31(4), 1001-1007 (2000).
70. Tattawasart U, Maillard JY, Furr JR, Russell AD. Development of resistance to Chlorhexidine diacetate and cetylpyridinium chloride in Pseudomonas stutzeri and changes in antibiotic susceptibility. J. Hosp. Infect. 42(3), 219-229 (1999).
71. Schwab SJ, Weiss MA, Rushton F et al. Multicenter clinical trial results with the LifeSite hemodialysis access system. Kidney Int. 62(3), 1026-1033 (2002).
72. Quarello F, Forneris G. Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock. Blood Purif. 20(1), 87-92 (2002).
73. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N. Engl. J. Med. 315(2), 91-96 (1986).
74. Bommer J, Vergetis W, Andrassy K, Hingst V, Borneff M, Huber W Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J. 41(1), 127-131 (1995).
75. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol. Dial. Transplant. 8(3), 235-239 (1993).
76. Cavdar C, Atay T, Zeybel M et al. Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis. Adv. Perit. Dial. 20, 67-70 (2004).
77. Lobbedez T, Gardam M, Dedier H et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years. Nephrol. Dial. Transplant. 19(12), 3140-3143 (2004).
78. Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbiol. Infect. Dis. 42(4), 283-290 (2002).
79. James MT, Conley J, Tonelli M, Manns BJ, MacRae J, Hemmelgarn BR. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann. Intern. Med. 148(8), 596-605 (2008).
80. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with polysporin ointment. J. Am. Soc. Nephrol. 14(1), 169-179 (2003).
81. Miles R, Johnson D. Use of honey to prevent infections associated with medical devices. In: Honey: A Modern Wound Management Product. Cooper R, Molan P, White R (Eds). Wounds UK Books, Dorset, UK, 91-105 (2008).
82. Cooper RA, Halas E, Molan PC. The efficacy of honey in inhibiting strains of Pseudomonas aeruginosa from infected burns. J. Burn Care Rehabil. 23(6), 366-370 (2002).
83. Cooper RA, Molan PC, Harding KG. The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds. J. Appl. Microbiol. 93(5), 857-863 (2002).
84. Namias N. Honey in the management of infections. Surg. Infect. (Larchmt) 4(2), 219-226 (2003).
85. Subrahmanyam M. Early tangential excision and skin grafting of moderate burns is superior to honey dressing: a prospective randomised trial. Burns 25(8), 729-731 (1999).
86. Molan PC. Potential of honey in the treatment of wounds and burns. Am. J. Clin. Dermatol. 2(1), 13-19 (2001).
87. Moore OA, Smith LA, Campbell F, Seers K, McQuay HJ, Moore RA. Systematic review of the use of honey as a wound dressing. BMC Complement. Altern. Med. 1, 2 (2001).
88. Dixon B. Bacteria can't resist honey. Lancet Infect. Dis. 3(2), 116 (2003).
89. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin. Infect. Dis., 47(1), 83-93 (2008).
90. Bleyer AJ. Use of antimicrobial catheter lock solutions to prevent catheter-related bacteremia. Clin. J. Am. Soc. Nephrol. 2(5), 1073-1078 (2007).
91. Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am. J. Kidney Dis. 48(4), 596-605 (2006).
92. Dogra GK, Herson H, Hutchison B et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am. Soc. Nephrol. 13(8), 2133-2139 (2002).
93. Kim SH, Song KI, Chang JW et al. Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: a prospective, randomized clinical trial. Kidney Int. 69(1), 161-164 (2006).
94. Saxena AK, Panhotra BR, Sundaram DS et al. Tunneled catheters' outcome optimization among diabetics on dialysis through antibiotic-lock placement. Kidney Int. 70(9), 1629-1635 (2006).
95. Sayearr N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin. Infect. Dis. 43(4), 474-484 (2006).
96. Weijmer MC, van den Dorpel MA, Van de Ven PJ et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J. Am. Soc. Nephrol. 16(9), 2769-2777 (2005).
97. Duncan N, Singh S, Amao Mea. A single centre randomised controlled trial of sodium citrate versus heparin line locks for cuffed central venous catheters (abstract). J. Am. Soc. Nephrol. 16, 451A (2005).
98. Power A, Duncan N, Singh SK et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am. J. Kidney Dis. 53(6), 1034-1041 (2009).
99. Traub WH, Leonhard B, Bauer D. Taurolidine: in vitro activity against multiple antibiotic resistant nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. Chemotherapy 39, 322-330 (1993).
100. Mermel LA, Parenteau S. Efficacy of the Biolink Catheter Lock Solution (CLS) for DIALOCK Hemodialysis Access Port and Catheters - an in-vitro model. On Site Program. International Conference on Nosocomial and Healthcare-Associated Infections. Sponsored by CDC, sdrg (2000).
101. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol. Dial. Transplant. 19(6), 1546-1551 (2004).
102. Metcalf SC, Chambers ST, Pithie AD. Use of ethanol locks to prevent recurrent central line sepsis. J. Infect. 49(1), 20-22 (2004).
103. Maharaj AR, Zelenitsky SA, Vercaigne LM. Effect of an ethanol/trisodium citrate hemodialysis catheter locking solution on isolates of Candida albicans. Hemodial. Int. 12(3), 342-347 (2008).
104. Takla TA, Zelenitsky SA, Vercaigne LM. Effect of ethanol/trisodium citrate lock on microorganisms causing hemodialysis catheter-related infections. J Vasc. Access 8(4), 262-267 (2007).
105. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. J. Antimicrob. Chemother. 62(5), 1024-1026 (2008).
106. Ackoundou-N'guessan C, Heng AE, Guenu S et al. Ethanol lock solution as an adjunct treatment for preventing recurrent catheter-related sepsis -first case report in dialysis setting. Nephrol. Dial. Transplant. 21(11), 3339-3340 (2006).
107. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J. Pediatr. Hematol. Oncol. 25(8), 616-621 (2003).
108. Onland W, Shin CE, Fustar S, Rushing T, Wong WY Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch. Pediatr. Adolesc. Med. 160(10), 1049-1053 (2006).
109. Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect. Dis. 7(10), 645-657 (2007).
110. Haxhe JJ, D'Hoore W A meta-analysis dealing with the effectiveness of Chlorhexidine and silver-sufhadiazine impregnated central venous catheters. J. Hosp. Infect. 40(2), 166-168 (1998).
111. Dahlberg PJ, Agger WA, Singer JR et al. Subclavian hemodialysis catheter infections: a prospective, randomized trial of an attachable silver-impregnated cuff for prevention of catheter-related infections. Infect. Control Hosp. Epidemiol. 16(9), 506-511 (1995).
112. European Best Practise Guidelines for Haemodialysis (Part 1). Haemodialysis-associated infection. Nephrol. Dial. Transplant. 17(Suppl. 7), 1-111 (2002).
113. European Best Practise Guidelines for Haemodialysis (Part 2). Haemodialysis-associated infection. Nephrol. Dial. Transplant. 22(Suppl. 2), ii1-ii118 (2007).
114. Wikdahl AM, Engman U, Stegmayr BG, Sorenssen JG. One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. Nephrol. Dial. Transplant. 12(1), 157-160 (1997).
115. Bennet-Jones DN, Martin JB, Barratt AJ, Duffy TJ, Naish PF, Aber GM. Prophylactic gentamicin in the prevention of early exit-site infectons and peritonitis in CAPD. Adv. Perit. Dial. 4, 147-150 (1988).
116. Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. Am. J. Kidney Dis. 36(5), 1014-1019 (2000).
117. Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. Scand. J. Urol. Nephrol. 26(2), 177-180 (1992).
118. Piraino B, Bailie GR, Bernardini J et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit. Dial. Int. 25(2), 107-131 (2005).
119. European Best Practice Guidelines for Peritoneal Dialysis. Peritoneal access. Nephrol. Dial. Transplant. 20(Suppl. 9), ix8-ix12 (2005).
120. Gadallah MF, Pervez A, el-Shahawy MA et al. Peritoneoscopic versus surgical placement of peritoneal dialysis catheters: a prospective randomized study on outcome. Am. J. Kidney Dis. 33(1), 118-122 (1999).
121. Tsimoyiannis EC, Siakas P, Glantzounis G et al. Laparoscopic placement of the Tenckhoff catheter for peritoneal dialysis. Surg. Laparosc. Endosc. Percutan. Tech. 10(4), 218-221 (2000).
122. Wright MJ, Bel'eed K, Johnson BF, Eadington DW, Sellars L, Farr MJ. Randomized prospective comparison of laparoscopic and open peritoneal dialysis catheter insertion. Perit. Dial. Int. 19(4), 372-375 (1999).
123. Jwo SC, Chen KS, Lee CC, Chen HY Prospective randomized study for comparison of open surgery with laparoscopic-assisted placement of Tenckhoff peritoneal dialysis catheter -a single center experience and literature review. J. Surg. Res. (2008) (Epub ahead of print).
124. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. J. Am. Soc. Nephrol. 15(10), 2735-2746 (2004). •• Well-conducted systematic review evaluating the impact of a wide range of catheter-related interventions on infections in peritoneal dialysis patients.
125. Ejlersen E, Steven K, Lokkegaard H. Paramedian versus midline incision for the insertion of permanent peritoneal dialysis catheters. A randomized clinical trial. Scand. J. Urol. Nephrol. 24(2), 151-154 (1990).
126. Rubin J, Didlake R, Raju S, Hsu H. A prospective randomized evaluation of chronic peritoneal catheters. Insertion site and intraperitoneal segment. ASAIO Trans. 36(3), M497-M500 (1990).
127. Moncrief JW, Popovich RP, Dasgupta M, Costerton JW, Simmons E, Moncrief B. Reduction in peritonitis incidence in continuous ambulatory peritoneal dialysis with a new catheter and implantation technique. Perit. Dial. Int. 13(Suppl. 2), S329-S331 (1993).
128. Park MS, Yim AS, Chung SH et al. Effect of prolonged subcutaneous implantation of peritoneal catheter on peritonitis rate during CAPD: a prospective randomized study. Blood Purif. 16(3), 171-178 (1998).
129. Danielsson A, Blohme L, Tranaeus A, Hylander B. A prospective randomized study of the effect of a subcutaneously 'buried' peritoneal dialysis catheter technique versus standard technique on the incidence of peritonitis and exit-site infection. Perit. Dial. Int. 22(2), 211-219 (2002).
130. Moncrief JW, Popovich R. Subcutaneous buried versus standard peritoneal dialysis catheter. Presented at: XVIII Annual CAPD Conference. Nashville, TN, USA, 24 February 1998.
131. Dasgupta MK, Perri D, Fox S. Exit-site infection, but not peritonitis, is reduced by the use of Moncrief-Popovich catheters in comparison to Tenckhoff catheters. Presented at: American Society of Nephrology Renal Week. Toronto, Canada, 13 October 2000.
132. Twardowski ZJ, Prowant BF, Pickett B, Nichols WK, Nolph KD, Khanna R. Four-year experience with swan neck presternal peritoneal dialysis catheter. Am. J. Kidney Dis. 27(1), 99-105 (1996).
133. Twardowski ZJ. Presternal peritoneal catheter. Adv. Ren. Replace. Ther. 9(2), 125-132 (2002).
134. Akyol AM, Porteous C, Brown MW. A comparison of two types of catheters for continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 10(1), 63-66 (1990).
135. Eklund BH, Honkanen EO, Kala AR, Kyllonen LE. Catheter configuration and outcome in patients on continuous ambulatory peritoneal dialysis: a prospective comparison of two catheters. Perit. Dial. Int. 14(1), 70-74 (1994).
136. Eklund BH, Honkanen EO, Kala AR, Kyllonen LE. Peritoneal dialysis access: prospective randomized comparison of the Swan neck and Tenckhoff catheters. Perit. Dial. Int. 15(8), 353-356 (1995).
137. Lye WC, Kour NW, van der Straaten JC, Leong SO, Lee EJ. A prospective randomized comparison of the swan neck, coiled, and straight Tenckhoff catheters in patients on CAPD. Perit. Dial. Int. 16(Suppl. 1), S333-S335 (1996).
138. Nielsen PK, Hemmingsen C, Friis SU, Ladefoged J, Olgaard K. Comparison of straight and curled Tenckhoff peritoneal dialysis catheters implanted by percutaneous technique: a prospective randomized study. Perit. Dial. Int. 15(1), 18-21 (1995).
139. Scott PD, Bakran A, Pearson R et al. Peritoneal dialysis access. Prospective randomized trial of 3 different peritoneal catheters - preliminary report. Perit. Dial. Int. 14(3), 289-290 (1994).
140. Johnson DW, Wong J, Wiggins KJ et al. A randomized controlled trial of coiled versus straight swan-neck Tenckhoff catheters in peritoneal dialysis patients. Am. J. Kidney Dis. 48(5), 812-821 (2006).
141. US Renal Data System Annual Data Report IV. Catheter-related factors and peritonitis risk in CAPD patients. Am. J. Kidney Dis. 20(Suppl. 2), 48-54 (1992).
142. Honda M, Iitaka K, Kawaguchi H et al. The Japanese National Registry data on pediatric CAPD patients: a ten-year experience. A report of the Study Group of Pediatric PD Conference. Perit. Dial. Int. 16(3), 269-275 (1996).
143. Warady BA, Sullivan EK, Alexander SR. Lessons from the peritoneal dialysis patient database: a report of the North American Pediatric Renal Transplant Cooperative Study. Kidney Int. 53, S68-S71 (1996).
144. Eklund B, Honkanen E, Kyllonen L, Salmella K, Kala AR. Peritoneal dialysis access: prospective randomized comparison of single-cuff and double-cuff straight Tenckhoff catheters. Nephrol. Dial. Transplant. 12(12), 2664-2666 (1997).
145. Miller TE, Findon G. Touch contamination of connection devices in peritoneal dialysis - a quantitative microbiologic analysis. Perit. Dial. Int. 17(6), 560-567 (1997).
146. Dryden MS, Ludlam HA, Wing AJ, Phillips I. Active intervention dramatically reduces CAPD-associated infection. Adv. Perit. Dial. 7, 125-128 (1991).
147. Hall G, Bogan A, Dreis S et al. New directions in peritoneal dialysis patient training. Nephrol. Nurs. J. 31(2), 149-154, 159-163 (2004). • Randomized, controlled trial demonstrating the benefit of enhanced training on exit-site infection and technique survival in peritoneal dialysis patients.
148. Luzar MA, Brown CB, Balf D et al. Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. Perit. Dial. Int. 10(1), 25-29 (1990).
149. Burkart JM, Hylander B, Durnell-Figel T, Roberts D. Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 10(1), 41-43 (1990).
150. Maiorca R, Cantaluppi A, Cancarini GC et al. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. Lancet 2(8351), 642-644 (1983).
151. Scalamogna A, De Vecchi A, Castelnovo C, Guerra L, Ponticelli C. Long-term incidence of peritonitis in CAPD patients treated by the Y set technique: experience in a single center. Nephron 55(1), 24-27 (1990).
152. Harris DC, Yuill EJ, Byth K, Chapman JR, Hunt C. Twin- versus single-bag disconnect systems: infection rates and cost of continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 7(11), 2392-2398 (1996).
153. Kiernan L, Kliger A, Gorban-Brennan N et al. Comparison of continuous ambulatory peritoneal dialysis-related infections with different 'Y-tubing' exchange systems. J. Am. Soc. Nephrol. 5(10), 1835-1838 (1995).
154. Li PK, Szeto CC, Law MC et al. Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study. Am. J. Kidney Dis. 33(3), 535-540 (1999).
155. Monteon F, Correa-Rotter R, Paniagua R et al. Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group. Kidney Int. 54(6), 2123-2128 (1998).
156. Cheng IK, Chan CY, Cheng SW et al. A randomized prospective study of the cost-effectiveness of the conventional spike, O-set, and UVXD techniques in continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 14(3), 255-260 (1994).
157. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group. Perit. Dial. Int. 9(3), 159-163 (1989).
158. Dryden MS, McCann M, Wing AJ, Phillips I. Controlled trial of a Y-set dialysis delivery system to prevent peritonitis in patients receiving continuous ambulatory peritoneal dialysis. J. Hosp. Infect. 20(3), 185-192 (1992).
159. Li PK, Chan TH, So WY, Wang AY, Leung CB, Lai KN. Comparisons of Y-set disconnect system (Ultraset) versus conventional spike system in uremic patients on CAPD: outcome and cost analysis. Perit. Dial. Int. 16(Suppl. 1), S368-S370 (1996).
160. Owen JE, Walker RG, Lemon J, Brett L, Mitrou D, Becker GJ. Randomized study of peritonitis with conventional versus O-set techniques in continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 12(2), 216-220 (1992).
161. Viglino G, Colombo A, Scalamogna A et al. Prospected randomized study of two Y devices in continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 9(3), 165-168 (1989).
162. Viglino G, Colombo A, Cantu P et al. In vitro and in vivo efficacy of a new connector device for continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 13(Suppl. 2), S148-S151 (1993).
163. Rottembourg J, Brouard R, Issad B, Allouache M, Jacobs C. Prospective randomized study about Y connectors in CAPD patients. Adv. Perit. Dial. 3, 107-113 (1987).
164. Lindholm T, Simonsen O, Krutzen L. Evaluation of a new take-off system (Ultraset) versus conventional spike system in uremic patients on CAPD: outcome and cost-analysis. Adv. Perit. Dial. 4, 262-265 (1988).
165. Daly CD, Campbell MK, MacLeod AM et al. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol. Dial. Transplant. 16(2), 341-347 (2001).
166. Luzar MA, Coles GA, Faller B et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N. Engl. J. Med. 322(8), 505-509 (1990).
167. Nouwen J, Schouten J, Schneebergen P et al. Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis. J. Clin. Microbiol., 44(6), 2233-2236 (2006).
168. No authors listed. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. J. Am. Soc. Nephrol. 7(11), 2403-2408 (1996).
169. Annigeri R, Conly J, Vas S et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit. Dial. Int. 21(6), 554-559 (2001).
170. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am. J. Kidney Dis. 39(2), 337-341 (2002).
171. Conly JM, Vas S. Increasing mupirocin resistance of Staphylococcus aureus in CAPD - should it continue to be used as prophylaxis? Perit. Dial. Int. 22(6), 649-652 (2002).
172. Thodis E, Bhaskaran S, Pasadakis P, Bargman JM, Vas SI, Oreopoulos DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit. Dial. Int. 18(3), 261-270 (1998).
173. Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. Adv. Perit. Dial. 16, 257-261 (2000).
174. Casey M, Taylor J, Clinard P et al. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit. Dial. Int. 20(5), 566-568 (2000).
175. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am. J. Kidney Dis. 27(5), 695-700 (1996).
176. Xu Y, Dong J, Zuo L. Is frequency of patient-physician clinic contact important in peritoneal dialysis patients? Perit. Dial. Int. 29(Suppl. 2), S83-S89 (2009).
177. Chu KH, Choy WY, Cheung CC et al. A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. Perit. Dial. Int. 28(5), 505-508 (2008).
178. Johnson DW, Clark C, Isbel NM et al. The Honeypot Study Protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Perit. Dial. Int. 29(3), 303-309 (2009). Describes the trial protocol for the first randomized, controlled trial of topical exit-site honey in peritoneal dialysis patients.
179. Montenegro J, Saracho R, Aguirre R, Martinez I, Iribar I, Ocharan J. Exit-site care with ciprofloxacin otologic solution prevents polyurethane catheter infection in peritoneal dialysis patients. Perit. Dial. Int. 20(2), 209-214 (2000).
180. Jassal SV, Lok CE. A randomized controlled trial comparing mupirocin versus polysponn triple for the prevention of catheter-related infections in peritoneal dialysis patients (the MP3 study). Perit. Dial. Int. 28(1), 67-72 (2008).
181. Blowey DL, Warady BA, McFarland KS. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. Adv. Perit. Dial. 10, 297-299 (1994).
182. Falagas ME, Fragoulis KN, Bliziotis IA. Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure - a meta-analysis of randomized controlled trials. Nephrol. Dial. Transplant. 21(9), 2536-2542 (2006).
183. Churchill DN, Taylor DW, Vas SI. Peritonitis in continuous ambulatory peritoneal dialysis patients: a randomized clinical trial of cotrimoxazole prophylaxis. Perit. Dial. Int. 8, 125-128 (1988).
184. Low DE, Vas SI, Oreopoulos DG et al. Prophylactic cephalexin ineffective in chronic ambulatory peritoneal dialysis. Lancet 2(8197), 753-754 (1980).
185. Sesso R, Parisio K, Dalboni A et al. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clin. Nephrol. 41(6), 370-376 (1994).
186. Troidle L, Kliger AS, Goldie SJ et al. Continuous peritoneal dialysis-associated peritonitis of nosocomial origin. Perit. Dial. Int. 16(5), 505-510 (1996).
187. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J. Am. Soc. Nephrol. 7(10), 2176-2182 (1996).
188. Zaruba K, Peters J, Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. Am. J. Kidney Dis. 17(1), 43-46 (1991).
189. Moreiras-Plaza M, Velio-Roman A, Samprom-Rodriguez M, Feijoo-Pineiro D. Ten years without fungal peritonitis: a single center's experience. Perit. Dial. Int. 27(4), 460-463 (2007).
190. Wong PN, Lo KY, Tong GM et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. Perit. Dial. Int. 27(5), 531-536 (2007).
191. Robitaille P, Merouani A, Clermont MJ, Hebert E. Successful antifungal prophylaxis in chronic peritoneal dialysis: a pediatric experience. Perit. Dial. Int. 15(1), 77-79 (1995).
192. Williams PF, Moncrieff N, Marriott J. No benefit in using nystatin prophylaxis against fungal peritonitis in peritoneal dialysis patients. Perit. Dial. Int. 20(3), 352-353 (2000).
193. Thodis E, Vas SI, Bargman JM, Singhal M, Chu M, Oreopoulos DG. Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 18(6), 583-589 (1998).
194. Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am. J. Kidney Dis. 28(4), 549-552 (1996).
195. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 44(4), 591-603 (2004). •• Well-conducted systematic review covering a wide range of antimicrobial strategies for the prevention of infection in peritoneal dialysis patients.
196. Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. Clin. Nephrol. 35(5), 198-206 (1991).
197. Nolphe KD, Prowant B, Serkes K et al. A randomized multicentre clinical trial to evaluate the effects of an ultravioulet germicidal system on peritonitis rate in continuous ambulatory peritoneal dialysis. Periton. Dial. Bull. 1, 19-24 (1985).
198. 201 British Renal Association. Clinical Practice Guideline Number 7: Haemodialysis: Vascular Access (2009) www.renal.org/pages/pages/guidelines/ current/haemodialysis.php (Accessed 22 July 2009)
199. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access. Guideline 7. Quality Improvement Programs www.kidney.org/professionals/kdoqi/guideline-uphd- pd-va/hd-guide7.htm (Accessed 22 July 2009)
200. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access. Guideline 2. Methods for Measuring and Expressing the Hemodialysis Dose www.kidney.org/ professionals/kdoqi/guideline-uphd-pd-va/hd-guide2.htm (Accessed 22 July 2009)
201. YEAR issues warning on tricitrasol dialysis catheter anitcoagulant www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucml73095.htm (Accessed 22 July 2009)
202. The CARI Guidelines - Caring for Australians with Renal Impairment. Haemodialysis: Vascular access (2000) www.cari.org.au/guidelines.php (Accessed 22 July 2009)
203. British Renal Association. Clinical Practice Guidelines Numbers 3 and 4. Peritoneal Access: Implantation Protocol and the Implantation Technique www.renal.org/pages/pages/guidelines/current/peritoneal-access.php (Accessed 22 July 2009)
204. The CARI Guidelines - Caring for Australians with Renal Impairment. Peritoneal dialysis: Evidence for Peritonitis Treatment and Prophylaxis (2004) www.cari.org.au/guidelines.php (Accessed 22 July 2009)
205. British Renal Association. Clinical Practice Guideline Number 5. Peritoneal dialysis: Infectious Complications (2007) www.renal.org/pages/pages/ guidelines/current/perkoneal-dialysis.php (Accessed 22 July 2009)